Navigation Links
TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
Date:4/23/2012

RESEARCH TRIANGLE PARK, N.C., April 23, 2012 /PRNewswire/ -- TeraDiscoveries, Inc., announced today a strategic relationship with Microsoft Corp. that will help it extend the reach of its drug discovery process. Microsoft is providing support and cloud computing time on Windows Azure that TeraDiscoveries will apply to identify inhibitors of 25 biological targets.

TeraDiscoveries will use its Inverse Design software that runs computational models to quickly scan virtual chemical libraries to find the strongest inhibitors of a specific biological target. The process identifies novel drug candidates that feature good clinical trial properties and demonstrate low probability of toxic side effects.

"Designing new drugs that bind to a specified protein target requires finding the best molecule in a vast chemical space. Our approach searches this space much more efficiently and cost-effectively than traditional methods," says Ed Addison, CEO of TeraDiscoveries. "Our strategic relationship with Microsoft enables us to partner with smaller pharmaceutical or medical research companies in the pursuit of these molecules."

"Windows Azure is an open and flexible cloud platform that has the scale and reliability to enable the type of computing power needed by software like Inverse Design," says Doug Hauger, General Manager, Windows Azure Business Development, Microsoft. "We're pleased to be able to support the work done by TeraDiscoveries to help advance its drug discovery process."

Companies can license Inverse Design and run it on Windows Azure to design, discover, or optimize new small molecule or peptide drugs for their targets. TeraDiscoveries also provides drug discovery services for companies seeking outside assistance.

TeraDiscoveries will be presenting Inverse Design in booth MP-10 at the Bio-IT World Conference & Expo taking place April 24 to 26, 2012, in Boston.

About TeraDiscoveries, Inc.

TeraDiscoveries is a drug discovery company located in Research Triangle Park, North Carolina. The company's Inverse Design software enables a paradigm shift to dramatically improve upon traditional drug discovery and design methods. This proprietary software combined with cloud computing enables the rapid and accurate discovery of novel drug candidates to serve as a catalyst for improved health and well-being. Visit www.teradiscoveries.com or contact Ed Addison at eaddison@teradiscoveries.com or (910) 398-1200.  

All product and company names herein may be trademarks of their respective owners.


'/>"/>
SOURCE TeraDiscoveries, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inverseons Founder and SAB Member Published in PNAS
2. Inverseon Announces Positive Phase IIa Asthma Study
3. TissuGlu® Surgical Adhesive Named 2012 Medical Design Excellence Awards Finalist
4. Ultragenyx Granted Orphan Designations in Europe for Two Lead Product Candidates, UX001 for HIBM and UX003 for MPS 7
5. GlobalSpec Medical Equipment Design Online Trade Show and Event Draws More Than 1,100 Attendees
6. Brainlab Curve Wins Coveted Red Dot Award: Product Design 2012
7. Government Rule Designed to Limit CT Scans in ERs Is Unreliable, Invalid and Inaccurate, Says ACEP
8. Sensors in Design Summit Launches at Design West
9. Medical Design & Manufacturing Conference to be Launched in Texas in March 2012
10. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
11. Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform ... leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... 12, 2017  Consumer reviews on the independent review site ... number one company for hearing aids, ranking it higher than ... ... by Consumers For Hearing Aids ... is an online store that provides high performance, state-of-the-art, German-engineered hearing ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... Nissar A. Darmani, PhD, has been ... patients suffering from chemotherapy-evoked nausea and vomiting. Dr. Darmani is Associate Dean of ... , The five-year grant is from the National Cancer Institute (NCI) arm of the ...
(Date:9/25/2017)... ... ... Introducing Panther, the revolutionary new iPhone case engineered to stop bacteria growth ... support for the #WarOnGrime. , Fact: iPhones are 18 times dirtier than toilets. 1 ... Panther iPhone cases are the first weapon in the war on bacteria with innovative ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... development solutions for drugs, biologics and consumer health products, today announced that two ... and validation of bioassays at two upcoming conferences. , At the BEBPA 10th ...
(Date:9/25/2017)... ... 2017 , ... PITTSBURGH...An inventor, from Richmond Hill, Ga., thought there needed to ... facilities, so he invented the COMPLETE PATIENT CHART. , The COMPLETE PATIENT CHART provides ... offers an improved alternative to paper charts and clipboards. As a result, it increases ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... METTLER TOLEDO ... place October 25-26, 2017 in Los Angeles, CA. The symposium will feature speakers from ... dealing with today's mass calibration technologies and help with planning for the future of ...
Breaking Medicine News(10 mins):